Chengdu Brilliant Harpoon

Chengdu Brilliant Harpoon Biotechnology Co., Ltd. is a specialized biotechnology subsidiary of Chengdu Brilliant Pharmaceutical Co., Ltd. (Beite Pharmaceutical), established in 2022 and based in Chengdu, China. The company serves as a key R&D hub for the parent group, focusing on the development of next-generation biological therapies, including dual-targeting CAR-T cell therapies and multispecific antibodies for oncology. Its pipeline includes innovative programs such as BHP01, a trispecific antibody targeting 4-1BB, DLL3, and PD-L1, and a dual-targeting CD133/PD-L1 CAR-T therapy. By leveraging advanced technology platforms and collaborating with academic institutions like West China Hospital, Chengdu Brilliant Harpoon aims to address significant unmet needs in the immuno-oncology space.